Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Durect Corp.

www.durect.com

Latest From Durect Corp.

Opioid-Sparing Hopes, Efficacy Worries Drive Inconclusive Advisory Cmte. On Durect's Posimir

US FDA's advisors produce tie vote on bupivacaine extended-release solution for post-surgical analgesia; proponents valued its potential to to cut opioid use, while opponents questioned its efficacy.

Advisory Committees Drug Review

What Does 2020 Hold For Biopharma?

Previewing the year to come, our journalists contacted more than 80 industry executives and experts for their views on what 2020 could hold for the biopharma sector. A series of articles based on these discussions were published by In Vivo’s sister publication Scrip. The following are highlights of the key issues that are top of mind for industry leaders this year, including digital tools, advanced therapies, the US election and manufacturing.

BioPharmaceutical Business Strategies

Durect's Posimir: NDA Resubmission Raises Similar Safety Issues

How to score adverse events for Durect's surgical pain treatment could determine whether US FDA advisory committee recommends bupivacaine extended-release solution; agency questions whether Posimir's formulation may cause neurological adverse events.

Advisory Committees Drug Safety

Esteve’s Tramadol/Celecoxib: US FDA Cites No Major Concerns, But Also No Advantages

Agency’s briefing document for 15 January review of the fixed-dose product combining an opioid and nonsteroidal anti-inflammatory reflects application of opioid benefit/risk framework described in June draft guidance.

Advisory Committees Drug Review
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Large Molecule
  • Medical Devices
    • Biomaterials
    • Implantable Devices
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Macromolecule
      • Site Specific
      • Transdermal
  • Therapeutic Areas
  • Hepatic (Liver)
  • Inflammation
  • Metabolic Disorders
  • Neurology, Nervous System
  • Ophthalmic
  • Renal System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Durect Corp.
  • Senior Management
  • James E Brown, DVM, Pres. & CEO
    Michael H Arenberg, CFO
    WeiQi Lin, MD, PhD, SVP, R&D, R&D Bus. Dev.
    Robert M Janosky, VP, Strategic Planning & Bus. Dev.
  • Contact Info
  • Durect Corp.
    Phone: (408) 777-1417
    10260 Bubb Rd.
    Cupertino, CA 95014-4166
    USA
UsernamePublicRestriction

Register